NCT02541383: Phase 3 - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT (CASSIOPEIA)
NCT02336815 : Phase 2 - Selinexor Treatment of Refractory Myeloma (STORM)
NCT02332850: Phase Ib Study of SAR650984 With Carfilzomib for Treatment of Relapsed Multiple Myeloma
Cancer Therapy: Oral Medication Basics: Information for Patients and Families (Targeted Therapy)
Cancer Therapy: Oral Medication Basics: Information for Patients and Families (Chemotherapy)
Myeloma UK - Myeloma Animations Series: Proteasome inhibitors in myeloma
NCT02538198: Phase 2 - Lenalidomide Maintenance in Plasma Cell Myeloma
Myeloma UK - Myeloma Animations Series: Immunotherapy in myeloma
NCT02415413: Phase 2 - Carfilzomib in Patients Under 65 With High Risk Smoldering MM GEM-CESAR trial
FDA Approved for RRMM: Elotuzumab (Empliciti) with lenalidomide and dexamethasone (Rd)
NCT02612779: Phase 2 - Elotuzumab in Combination With Pomalidomide and Low dose Dex Vs Nivo/Elo
NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)
FDA Approved for RRMM: Panobinostat (Farydak) Capsules + Bortezomib (Velcade) and Dexamethasone
Myeloma UK - Myeloma Animations Series: Genetic causes of myeloma
Nature Videos: Tumour immunology and immunotherapy
FDA Approved for RRMM: Kyprolis (carfilzomib) + Revlimid (lenalidomide) and Dexamethasone (KRd)
NCT02495922: Phase 3 - Elotuzumab in VRD Induction /Consolidation and Len maint in NDMM(GMMG-HD6)
FDA Approved for RRMM: Daratumumab (Darzalex)
FDA Approved for NDMM: Lenalidomide (Revlimid)